Cancer Supportive Care Drugs Market size was valued at US$ 11.54 Bn. in 2022 at CAGR 5.7 and the cancer segment is likely to dominate the growth of the Cancer Supportive Care Drugs market in the future.
Cancer Supportive Care Drugs Market Overview:
Cancer supportive medications are used to treat infections generated by chemotherapy as well as other infections. These medications are intended to protect the body's organs against the damaging effects of cancer treatment. These supportive medications, also known as protective pharmaceuticals, are generally administered with cancer therapies to prevent infections. Due to different factors such as a low blood cell count, cancer therapies are often interrupted or doses are reduced. Cancer supportive medications, such as colony-stimulating factors (CSFs), assist patients in continuing their cancer treatment. Cancer Supportive Care Drugs Market Dynamics:
Cancer Supportive Care Drugs Market size was valued at US$ 11.54 Bn. in 2022 and the total revenue is expected to grow at 5.7% through 2022 to 2029, reaching nearly US$ 17.01 Bn.
The growth is expected to be driven by a large number of adverse effects associated with cancer therapy, increasing penetration of biosimilars, rising healthcare expenditures, and the availability of effective treatment options, including target-specific and personalized treatments. The International Agency for Research on Cancer (IARC) estimates that 12.7 million individuals are diagnosed with cancer each year, with 7.6 million fatalities. The most common cancer types with the biggest need for supportive care medications are lung and breast cancer.
China and India are two of the most potential markets for cancer supportive care growth. Factors like rising biosimilar use, favorable healthcare reforms, and a low-cost base are boosting the industry in these two countries. The cancer supportive care segment still has several unmet demands. The current therapeutic options merely provide symptomatic alleviation. Effective analgesics with a decreased risk of tolerance and addiction are still a major unmet need in the cancer supportive medication market.
According to the World Health Organization (WHO), around 18.1 million new cases of cancer were recognized in 2018, with approximately 9.6 million deaths attributed to cancer. Furthermore, statistics show that the prevalence of cancer has been rising over time. As a result, the number of patients seeking cancer treatment has increased. Cancer supportive care medications are prescribed to help patients cope with the negative effects of cancer treatment. As a result, rising cancer rates are directly linked to the expansion of this sector. Rising disposable income and a better healthcare system have also made it easier for consumers to obtain cancer supportive care medications, which is fueling the market's growth.
Cancer Supportive Care Drugs Market Segment Analysis:
The G-CSF segment is dominating the Therapeutic Class segment of the Cancer Supportive Care Drugs Market:
G-CSF is a sort of growth factor that aids in the production of white blood cells in the bone marrow, lowering the risk of infection following some forms of cancer treatment. G-CSF also promotes the movement of stem cells from the bone marrow into the bloodstream. The cells in the bone marrow that produce red blood cells, white blood cells, and platelets are known as stem cells. G-CSF is given to encourage the bone marrow to create and release stem cells into the bloodstream. After that, the stem cells are collected before being subjected to high-dose chemotherapy. Chemotherapy at a high dose inhibits your bone marrow from generating blood cells. Brands such as Amgen's Neupogen, Neulasta, Epogen, and Xgeva, Merck's Emend, Roche's NeoRecormon, Helsinn's Aloxi, Heron's Sustol, and Cinvanti are among those mentioned in the research.
Cancer Supportive Care Drugs Market Regional Insights:
North America is estimated to dominate the growth of the Cancer Supportive Care Drugs Market.
North America has one of the world's highest cancer prevalence rates. Even though the number of biosimilars launched in the United States is modest, biosimilar penetration is expected to rise due to biologics' average price being twice that of biosimilars. Cancer prevalence in the United States was predicted to be 439.2 per 100,000 in 2018, according to the National Institute of Health. According to the Canadian Cancer Society, in 2017, there were 206,200 new cancer diagnoses and 80,800 cancer-related deaths in Canada. Even though high incidence places a burden on the country's population, the United States and Canada have built healthcare systems and so invest a significant amount of money in cancer treatment and research. As a result, these countries attract a large number of market participants.
The objective of the report is to present a comprehensive analysis of the Cancer Supportive Care Drugs Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.
PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding the Cancer Supportive Care Drugs Market dynamics, structure by analyzing the market segments and projecting the Cancer Supportive Care Drugs Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Cancer Supportive Care Drugs Market make the report investor?s guide.Cancer Supportive Care Drugs Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Cancer Supportive Care Drugs Market Key Player
2. Johnson & Johnson
5. Helsinn Healthcare
6. Heron Pharma
8. Novartis AG
9. F. Hoffmann-La Roche
1. What is the Cancer Supportive Care Drugs Market value in 2022?
Ans: Cancer market value in 2022 was estimated as 11.54 Billion USD.
2. What is the Cancer Supportive Care Drugs market growth?
Ans: The market is anticipated to grow with a CAGR of 5.7% in the forecast period and is likely to reach USD 17.02 Billion by the end of 2029.
3. Which regional segment is expected to dominate the Cancer Supportive Care Drugs Market during the forecast period?
Ans: North America dominates the demand in theGlobal cancer supportive care products market. By the end of 2022, the region of North America, backed by the developed country of the U.S., is poised to provide for a demand share of 44.2%.
4. Who are the key players in the market?
Ans: Some key players operating in the dental fillings market include Amgen, Johnson & Johnson, Merck, Roche, Helsinn Healthcare, Heron Pharma, and Tesaro.
5. What is the key driving factor for the growth of the market?
Ans: A large number of side-effects associated with cancer treatment, increasing uptake of biosimilars, rising expenditure on healthcare, and availability of effective treatment methods, including target-specific and tailored treatments are anticipated to drive the growth.
Table of content
Table of Contents
1Global Cancer Supportive Care Drugs Market: Research Methodology
2Global Cancer Supportive Care Drugs Market: Executive Summary
2.1 Market Overview and Definitions
2.1.1. Introduction toGlobal Cancer Supportive Care Drugs Market
2.1.1. Key Findings
2.1.2. Recommendations for Investors
2.1.3. Recommendations for Market Leaders
2.1.4. Recommendations for New Market Entry
3.Global Cancer Supportive Care Drugs Market: Competitive Analysis
3.1 MMR Competition Matrix
3.1.1. Market Structure by region
3.1.2. Competitive Benchmarking of Key Players
3.2 Consolidation in the Market
3.2.1 M&A by region
3.3 Key Developments by Companies
3.4 Market Drivers
3.5 Market Restraints
3.6 Market Opportunities
3.7 Market Challenges
3.8 Market Dynamics
3.9 PORTERS Five Forces Analysis
3.11 Regulatory Landscape by region
? North America
? Asia Pacific
? The Middle East and Africa
? Latin America
3.12 COVID-19 Impact
4.Global Cancer Supportive Care Drugs Market Segmentation
4.1Global Cancer Supportive Care Drugs Market, by Therapeutic Class (2022-2029)
? G-CSFs (Granulocyte-colony Stimulating Factors)
? ESAs (Erythropoiesis Stimulating Agents)
5. North America Cancer Supportive Care Drugs Market (2022-2029)
5.1 North American Cancer Supportive Care Drugs Market, by Therapeutic Class (2022-2029)
? G-CSFs (Granulocyte-colony Stimulating Factors)
? ESAs (Erythropoiesis Stimulating Agents)
5.7 North America Cancer Supportive Care Drugs Market, by Country (2022-2029)
? United States
6. Asia Pacific Cancer Supportive Care Drugs Market (2022-2029)
6.1. Asia Pacific Cancer Supportive Care Drugs Market, by Therapeutic Class (2022-2029)
6.2. Asia Pacific Cancer Supportive Care Drugs Market, by Country (2022-2029)
? South Korea
? Rest Of APAC
7. Middle East and Africa Cancer Supportive Care Drugs Market (2022-2029)
7.1. Middle East and Africa Cancer Supportive Care Drugs Market, by Therapeutic Class (2022-2029)
7.3. Middle East and Africa Cancer Supportive Care Drugs Market, by Country (2022-2029)
? South Africa
? Rest Of ME&A
8. Latin America Cancer Supportive Care Drugs Market (2022-2029)
8.1. Latin America Cancer Supportive Care Drugs Market, by Therapeutic Class (2022-2029)
8.3 Latin America Cancer Supportive Care Drugs Market, by Country (2022-2029)
? Rest Of Latin America
9. European Cancer Supportive Care Drugs Market (2022-2029)
9.1. European Cancer Supportive Care Drugs Market, by Therapeutic Class (2022-2029)
9.3 European Cancer Supportive Care Drugs Market, by Country (2022-2029)
? Rest Of Europe
10. Company Profile: Key Players
10.1 Novartis AG
10.1.1 Company Overview
10.1.2 Financial Overview
10.1.3 Geographic Footprint
10.1.4 Grade Portfolio
10.1.5 Business Strategy
10.1.6 Recent Development
10.3 Johnson & Johnson
10.6 Helsinn Healthcare
10.7 Heron Pharma
10.9 Novartis AG
10.10 F. Hoffmann-La Roche
10.12 Heron Pharma
10.13 Helsinn healthcare
10.14 Sun pharmaceuticals
11. Primary Key Insights